Browse

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

FDA's new CBER chief promises normalcy, an weight loss drug without GLP-1s, and more biotech news from The Readout

Managing risk factors is the key to further progress in reducing deaths from coronary artery disease, a new study finds.